Canadian Agency for Drugs and Technologies in Health

But of course, it's putting in the time and having the resources at the organization as well, and making sure you have the capacity to figure out how you're gonna capture that and report on that.

Gail got a shout-out for the number of submissions that was done to Canada Drug Agency in a report that was done by our friends.

So by a report that was done by ZBricks.

So that article had come out, and I read it, and it was a nice overview as to which groups had done submissions and some quantification of it as well.

This is where I was going back to, is they're also in human resources offices.

So we ship those pamphlets to human resources offices so that they can provide them for their employees as they might need them.

So Gail, speaking behind the scenes, we talked earlier about how many submissions your organization has done on behalf of patient voice to Canada Drug Agency, and thinking about all the amazing work that I've seen over the years from patient organizations, I'm curious what your thoughts are.

What do you wish the general public knew a little bit more about the value and the great work that patient organizations bring forward?

And that's why adverse events management is so important.

Now, these are the CDA guidelines, the Canadian Drug Agency.

You know, again, I think all of us believe that in the first-line setting, an ELK TKI should be used.

Crizotinib was the first TKI made onto the scene, but I don't think anyone would use it in the first-line setting today.

When we first got that immuno-oncology, went through the health approval process, we get to go out and be part of that process.

And it talks to melanoma because the first submission we got to do to the Canadian Drug Agency, we did a survey out to the patients that we had helped, because we'd already started helping patients, but we had lost every single patient that we had tried to help.

In those first years of Save Your Skin, we only really had Edmonton, Alberta treating.

So every patient that came to us, we were sending over to the cross to try to get them on either one or two of those treatments.